Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

NEUROBIOLOGY OF DISEASE

卷:141

Article

Espadas, Isabel^1,2  Keifman, Ettel¹  Palomo-Garo, Cristina^2,3,4  Burgaz, Sonia^2,3,4  Garcia, Concepcion^2,3,4  Fernandez-Ruiz, Javier^2,3,4  Moratalla, Rosario^1,2 

[1] CSIC, Inst Cajal, Madrid, Spain

[2] ISCIII, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain

[3] Univ Complutense, Inst Univ Invest Neuroquim, Fac Med, Dept Bioquim & Biol Mol, Madrid, Spain

[4] Inst Ramon y Cajal Invest Sanitaria IRYCIS, Madrid, Spain

关键词: Parkinson's disease;    L-DOPA;    L-DOPA-induced dyskinesia;    Cannabinoids;    Delta(9)-THCV;    CB1 receptors;    CB2 receptors;   

DOI  :  10.1016/j.nbd.2020.104892

来源: Elsevier

【 摘 要 】

The antioxidant and CB2 receptor agonist properties of Delta(9)-tetrahydrocannabivarin (Delta(9)-THCV) afforded neuro-protection in experimental Parkinson's disease (PD), whereas its CB I receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated the anti-dyskinetic potential of Delta(9)-THCV (administered i.p. at 2 mg/kg for two weeks), which had not been investigated before. This objective was investigated after inducing dyskinesia by repeated administration of L-DOPA (i.p. at 10 mg/kg) in a genetic model of dopaminergic deficiency, Pitx3(ak) mutant mice, which serves as a useful model for testing anti-dyskinetic agents. The daily treatment of these mice with L-DOPA for two weeks progressively increased the time spent in abnormal involuntary movements (AIMs) and elevated their horizontal and vertical activities (as measured in a computer-aided actimeter), signs that reflected the dyskinetic state of these mice. Interestingly, when combined with L-DOPA from the first injection, Delta(9)-THCV delayed the appearance of all these signs and decreased their intensity, with a reduction in the levels of FosB protein and the histone pAcH3 (measured by immunohistochemistry), which had previously been found to be elevated in the basal ganglia in L-DOPA-induced dyskinesia. In addition to the anti-dyskinetic effects of Delta(9)-THCV when administered at the onset of L-DOPA treatment, Delta(9)-THCV was also effective in attenuating the intensity of dyskinesia when administered for three consecutive days once these signs were already present (two weeks after the onset of L-DOPA treatment). In summary, our data support the anti-dyskinetic potential of Delta(9)-THCV, both to delay the occurrence and to attenuate the magnitude of dyskinetic signs. Although further studies are clearly required to determine the clinical significance of these data in humans, the results nevertheless situate Delta(9)-THCV in a promising position for developing a cannabinoid-based therapy for patients with PD.